Processa Pharmaceuticals, Inc.

Stocks

PCSA

US74275C4033

Market Closed - Nasdaq 23:30:00 15/09/2026 +03			5-day change	1st Jan Change
1.957 ^USD	+4.08%		-9.41%	-32.06%

08-14	Processa Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
07-30	Processa Pharmaceuticals, Inc. announced that it has received $200 million in funding from a group of investors	CI

Transcript : Processa Pharmaceuticals, Inc. - M&A Call

Published on 07/30/2026 at 12:05 am +03 - Modified on 08/05/2026 at 12:47 am +03

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Thank you for standing by. My name is Demi, and I'll be your conference operator today. At this time, I would like to welcome everyone to the Processa

This article is reserved for our subscribers.

To unlock the article,
subscribe!

Unlimited browsing across the entire site

Access to all news and data

US, Europe, and Asia portfolios

Ad-free reading

Pro Tools : expert screeners, historical financials, PDF reports, investment themes, and earnings transcripts

Latest news about Processa Pharmaceuticals, Inc.

08-14	Processa Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
07-30	Processa Pharmaceuticals, Inc. announced that it has received $200 million in funding from a group of investors	CI
07-30	Processa Pharmaceuticals, Inc. acquired Vidya Therapeutics, Inc. for approximately $320 million.	CI
07-30	Processa Pharmaceuticals, Inc. - M&A Call
07-29	Processa Pharmaceuticals, Inc. announced that it expects to receive $200 million in funding from a group of investors	CI
07-29	Processa buys Vidya Therapeutics, raises $200 million for drug trials	RE
07-29	Processa Pharmaceuticals, Inc. Announces Appointment of Sheila Gujrathi as Director	CI
07-28	Processa Pharmaceuticals, Inc. announced that it expects to receive $200 million in funding	CI
07-27	Deals of the day-Mergers and acquisitions	RE
05-07	Processa Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-01	Processa Pharmaceuticals, Inc. Announces Transition of Employment Status of Sian Bigora, Chief Development and Regulatory Officer, Effective May 1, 2026	CI
03-20	Bio-Path Holdings, Inc. Announces Scientific Advisory Board Appointments, Effective February 10, 2026	CI
03-18	Processa Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-18	Processa Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	CI
02-20	Processa Pharmaceuticals, Inc. Announces Expiration of Binding Term Sheet with Intact Therapeutics	CI

Chart Processa Pharmaceuticals, Inc.

Duration

Period

PCSA: Dynamic Chart

Company Profile

Sector

More about the company

Income Statement and Estimates

More financial data